Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Status:	Active, not recruiting
Conditions:	Dermatology
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	18 - 65
Updated:	2/24/2018
Start Date:	December 2015
End Date:	May 2018

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active
pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in
acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic
melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be
evaluated for the treatment of common warts.

Inclusion Criteria:

- Male and female subjects between the ages of 18 and 65 years of age, inclusive

- Subjects presenting with at least one verruca vulgaris (common cutaneous, plantar, and
periungual) warts for at least 4 weeks, but no more than 3 years

- Subject's common warts for treatment must measure between 3 and 20 mm and be located
on hands, feet, limbs and/or trunk. A maximum of four (4) cutaneous single warts or
one (1) area of clustered or adjacent warts up to 80 mm will be treated

Exclusion Criteria:

- Genital warts may not be selected as target warts

- Subjects that are immuno-compromised

- Presence of systemic or localized diseases, conditions, or medications that could
interfere with assessment of safety and efficacy or that compromise immune function

We found this trial at

sites

Mount Sinai St. Luke's

New York, New York 10025

from

New York, NY